← Back
Johnson & Johnson
JNJ · listed on the New York Stock Exchange · worth $630.04 billion
$271.04
+0.86% on Oct 28
One insider buy in the last year, $257.7K in all. None in the last two weeks. Eight members of Congress reported trading Johnson & Johnson in the last year.
Green dot = an insider bought red = sold◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
2.4B shares
100% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, one insider bought Johnson & Johnson stock and nine insiders sold. None of the 25 sales is marked on its filing as planned in advance; all by company executives. The biggest seller was Joaquin Duato, CEO and Chairman of the Board.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
Director
John G. Morikis
Bought $257.7K on Nov 26, 2025 — 1,250 shares at $206.15, 68% of what they now own.
1 of 1 earlier purchase did better than the S&P 500
Planned sales
Form 144 notices filed for Johnson & Johnson in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
Chair Timothy Schmid filed to sell 33,597 shares on 2 Sep; sold 33,597 by 2 SepNotice on SEC.gov
Jennifer L. Taubert filed to sell 15,000 shares on 17 Aug; sold 15,000 by 17 AugNotice on SEC.gov
CEO Joaquin Duato filed to sell 123,291 shares on 13 Aug; no sale reported yetNotice on SEC.gov
US Congress
Members of Congress who reported trading Johnson & Johnson in the last year. They have up to 45 days to report, so the newest trades show up late.
MemberTradeAmountWhose accountTradedReported
All reports
Every insider trade and SEC report we hold for Johnson & Johnson.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Aug 18SoldJennifer L. TaubertAug 18 · Traded Aug 17 · EVP, WWC. Innovative Medicine15,000 @ $263.36$3.95M
26 more with Pro →Analysts, earnings and news
Analysts' price target
$252.87 average
23 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
3 of 4 quarters above
Q1 '26$2.70 a share+$0.02
Q4 '25$2.46 a share−$0.00
Q3 '25$2.80 a share+$0.04
Q2 '25$2.77 a share+$0.09